Lipids & metabolic liver disease
The Effect of Testosterone Replacement Therapy on Nonalcoholic Fatty Liver Disease in Older Hypogonadal Men
Authors' conclusion
Our study did not show improvement of NAFLD in older hypogonadal men after 12 months of T vs placebo treatment, as assessed by 3 clinical scores and liver CT for hepatic steatosis. Future studies with longer treatment duration and additional NAFLD diagnostic modalities as primary outcome are warranted.
Study context
- Population
- Older hypogonadal men with total T < 275 ng/dL from The T Trials
- Participants
- 479 men
- Comparison
- Testosterone vs placebo
- Tn = 246
- Placebon = 233reference
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
12 months
- T vs Placebo: P = 0.98
- T vs Placebo: P = 0.67
- T vs Placebo: P = 0.52
- T vs Placebo: P = 0.24
- T vs Placebo: P = 0.74
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The Effect of Testosterone Replacement Therapy on Nonalcoholic Fatty Liver Disease in Older Hypogonadal Men. J Clin Endocrinol Metab. Published 1 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →